Drugs / EP262
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06645704 | Oct → Dec 2024 | — | Escient Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06050928 | Aug 2023 → Oct 2024 | chronic inducible urticaria | Escient Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06144424 | Oct 2023 → Jul 2024 | atopic eczema | Escient Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT06077773 | Sep 2023 → Dec 2024 | chronic idiopathic urticaria | Escient Pharmaceuticals, Inc | Terminated | Missed primary Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06077773 ↗ |
| Route | Oral | “Oral EP262” NCT06050928 ↗ |